孕前扩展性携带者筛查在IVF与普通人群中的临床有效性与效用
该研究分析了2017年1月至2020年1月间3877名无遗传病家族史个体,采用基于ACOG推荐标准开发的聚焦性ECS面板。结果显示10.4%个体携带至少一个基因的致病/可能致病变异,766对夫妇中2.6%为高风险夫妇,随访的15对高风险夫妇均选择PGT-M/PGT-A,其中6对已完成PGT周期并获得妊娠。
要点
- 孕前ECS在高风险夫妇中检出率达2.6%,在IVF与自然受孕人群中均显示临床效用。
- 携带者总体检出率为10.4%,最常见的风险病种为囊性纤维化、脆性X综合征、脊髓性肌萎缩和β-地中海贫血/镰状细胞贫血。
- 随访的高风险夫妇全部选择通过PGT-M/PGT-A修改生育计划,其中40%已完成PGT周期并获得妊娠。
核心结论
- 孕前扩展性携带者筛查在高风险夫妇中具有较高的检出率,且高风险夫妇中选择IVF/PGT的比例很高,证明其在IVF和普通人群中具有临床效用。
研究设计与样本
- 研究纳入2017年1月至2020年1月间3877名无遗传病家族史个体,其中1212名为配子捐赠者,2665名为计划怀孕的患者(来自IVF和自然受孕组)。
- 非捐赠者队列中1133名作为个体患者分析,其余作为夫妇分析,共766对夫妇。
- 采用基于ACOG推荐标准(患病率、携带率、严重性)开发的聚焦性ECS面板,包括高外显率严重儿童期疾病。
主要发现
- 402名个体(10.4%)显示至少一个受检基因的致病/可能致病变异。
- 766对夫妇中,173对(22.6%)有一方为携带者,20对(2.6%)被确认为高风险夫妇。
- 高风险夫妇中,5对(0.7%)为囊性纤维化风险,5对(0.7%)为脆性X综合征风险,4对(0.5%)为脊髓性肌萎缩风险,4对(0.5%)为β-地中海贫血/镰状细胞贫血风险,1对(0.1%)为Smith-Lemli-Opitz综合征风险,1对(0.1%)为Duchenne/Becker肌营养不良风险。
- 通过一名SMN1基因致病变异携带者的家族 cascade 检测,识别出1对高风险夫妇。
- 15对高风险夫妇(来自IVF和自然受孕组)均成功随访,全部(15/15)通过接受PGT-M和PGT-A修改了生育计划。
关键数值与推荐
- 高风险夫妇定义:双方携带同一基因的常染色体隐性致病/可能致病变异,或女性为X连锁致病/可能致病变异携带者。
- 高风险夫妇检出率用于定义ECS方法的临床有效性。
- 临床效用通过监测高风险夫妇的生育决策来评估。
临床怎么用
- 孕前ECS可识别高风险夫妇,为其提供通过IVF/PGT降低受累妊娠风险的决策支持。
- ECS结果可指导高风险夫妇选择PGT-M/PGT-A等辅助生殖技术,实现生殖自主。
- 在IVF背景下,孕前ECS有助于整合单基因病筛查与胚胎植入前检测。
局限性
- 使用有限的核心基因-疾病对面板可能低估可检测的携带者和高风险夫妇率。
- 研究未报告外部资金支持,部分作者为Igenomix Italy雇员,C.S.为Igenomix科学委员会主席。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the clinical validity and utility of preconception Expanded Carrier Screening (ECS) application on the management of prospective parents? SUMMARY ANSWER: The high detection rate of at-risk couples (ARCs) and the high proportion opting for IVF/preimplantation genetic testing (PGT) treatment demonstrate the clinical utility of ECS in the preconception space in IVF and general population. WHAT IS KNOWN ALREADY: About 2-4% of couples are at risk of conceiving a child with an autosomal recessive or X-linked genetic disorder. In recent years, the increasing cost-effectiveness of genetic diagnostic techniques has allowed the creation of ECS panels for the simultaneous detection of multiple recessive disorders. Comprehensive preconception genetic screening holds the potential to significantly improve couple's genetic risk assessment and reproductive planning to avoid detectable inheritable genetic offspring. STUDY DESIGN, SIZE, DURATION: A total of 3877 individuals without a family history of genetic conditions were analyzed between January 2017 and January 2020. Of the enrolled individuals, 1212 were gamete donors and 2665 were patients planning on conceiving from both the IVF and the natural conception group. From the non-donor cohort, 1133 were analyzed as individual patients, while the remaining ones were analyzed as couples, for a total of 766 couples. PARTICIPANTS/MATERIALS, SETTING, METHODS: A focused ECS panel was developed following American College of Obstetrics and Gynecology ACOG-recommended criteria (prevalence, carrier rate, severity), including highly penetrant severe childhood conditions. Couples were defined at-risk when both partners carried an autosomal recessive pathogenic/likely pathogenic variant (PLP) on the same gene or when the woman was a carrier of an X-linked PLP variant. ARC detection rate defined the clinical validity of the ECS approach. Clinical utility was evaluated by monitoring ARCs reproductive decision making. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 402 individuals (10.4%) showed PLP for at least one of the genes tested. Among the 766 couples tested, 173 showed one carrier partner (22.6%), whereas 20 couples (2.6%) were found to be at increased risk. Interestingly, one ARC was identified as a result of cascade testing in the extended family of an individual carrying a pathogenic variant on the Survival Of Motor Neuron 1SMN1 gene. Of the identified ARCs, 5 (0.7%) were at risk for cystic fibrosis, 5 (0.7%) for fragile X syndrome, 4 (0.5%) for spinal muscular atrophy, 4 (0.5%) for Beta-Thalassemia/Sickle Cell Anemia, 1 (0.1%) for Smith-Lemli-Opitz Syndrome and 1 (0.1%) for Duchenne/Becker Dystrophy. Fifteen ARCs were successfully followed up from both the IVF and the natural conception groups. All of these (15/15) modified their reproductive planning by undergoing ART with Preimplantation Genetic Testing for Monogenic disease and Aneuploidies (PGT-M and PGT-A). To date, 6/15 (40%) couples completed their PGT cycle with euploid/unaffected embryos achieving a pregnancy after embryo transfer and three of them have already had an unaffected baby. LIMITATIONS, REASONS FOR CAUTION: The use of a limited panel of core gene-disease pairs represents a limitation on the research perspective as it can underestimate the rate of detectable carriers and ARCs in this cohort of prospective parents. Expanding the scope of ECS to a larger panel of conditions is becoming increasingly feasible, thanks to a persistent technological evolution and progressive cataloging of gene-disease associations. WIDER IMPLICATIONS OF THE FINDINGS: These results highlight the potential clinical validity and utility of ECS in reducing the risk of a pregnancy affected by a detectable inheritable genetic condition. The steady reduction in the costs of genetic analyses enables the expansion of monogenic testing/screening applications at the preimplantation stage, thus, providing valid decisional support and reproductive autonomy to patients, particularly in the context of IVF. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. A.C., M.F., S.C., M.P., L.G., and C.P. are employees of Igenomix Italy. C.S. is the head of the scientific board of Igenomix. TRIAL REGISTRATION NUMBER: N/A.
引用
- Capalbo A, Fabiani M, Caroselli S, et al. Clinical validity and utility of preconception expanded carrier screening for the management of reproductive genetic risk in IVF and general population. Hum Reprod. 2021. PMID: 34021342. doi:10.1093/humrep/deab087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。